KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Amortizatization of Intangibles (2018 - 2019)

BeOne Medicines (ONC) reported Amortizatization of Intangibles of -$51000.0 for Q3 2019, up 98.85% year-over-year from -$25647.3 in Q3 2018, and up 95.9% on a QoQ basis from -$1.2 million in Q2 2019.

BeOne Medicines (ONC) has 2 years of Amortizatization of Intangibles data on file, last reported at -$51000.0 in Q3 2019.

  • Quarterly Amortizatization of Intangibles rose 98.85% year-over-year to -$51000.0 in Q3 2019, while the trailing twelve-month figure through Sep 2019 was -$7.3 million (down 64.29% YoY) and the FY2018 annual result came in at -$8.0 million, changed N/A from the prior year.
  • Amortizatization of Intangibles improved to -$51000.0 in Q3 2019 per ONC's latest filing, from -$1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at -$51000.0 in Q3 2019 and bottomed at -$4.4 million in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 13,267.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 BeOne Medicines - - 1.35 Bn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2019 -51,000.00
Sep 30, 2019 -51,000.00
Jun 30, 2019 -1.24 Mn
Jun 30, 2019 -1.24 Mn
Mar 31, 2019 -2.41 Mn
Mar 31, 2019 -2.41 Mn
Dec 31, 2018 -3.59 Mn
Dec 31, 2018 -3.59 Mn
Sep 30, 2018 -4.44 Mn
Sep 30, 2018 -4.44 Mn